MLV Capital reiterated TRANSCEPT PHAR (NASDAQ: TSPT) to Buy with price target $21
MLV Capital reiterated TRANSCEPT PHAR (NASDAQ: TSPT) to Buy with price target
$21. Previously MLV Capital reiterated TRANSCEPT PHAR (NASDAQ: TSPT) to Buy with price target $15 on 07/18/2011, when the stock price was $4.70.
Transcept Pharmaceuticals, Inc. (Transcept) is a specialty pharmaceutical company focused on the development and commercialization of products that address important therapeutic needs in the field of neuroscience. The lead Transcept product candidate, Intermezzo, is a sublingual low dose formulation of zolpidem that has been developed for use as-needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep. The Company has completed all scheduled clinical trials on behalf of Intermezzo and submitted a New Drug Application (NDA), to the United States Food and Drug Administration (FDA), on September 30, 2008, which was accepted for filing on December 15, 2008. On January 30, 2009, Transcept completed a merger with Novacea, Inc. As part of the transaction, Novacea changed its name to Transcept Pharmaceuticals, Inc.
is a boutique investment bank and institutional broker-dealer focused on providing independent financial advice and unique capital markets expertise to corporate and institutional clients in capital intensive industries such as metals and mining, life sciences, energy and real estate. With a focus on raising money efficiently for clients, MLV has rapidly become a leader in the At-the-Market(ATM) transaction market.